(0.09%) 5 521.75 points
(0.13%) 39 896 points
(0.19%) 19 788 points
(-0.02%) $81.61
(0.57%) $2.83
(-0.24%) $2 338.80
(0.20%) $29.59
(0.41%) $1 005.90
(0.03%) $0.932
(-0.06%) $10.53
(0.01%) $0.788
(-0.85%) $87.25
0.00% $ 51.99
Live Chart Being Loaded With Signals
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States...
Stats | |
---|---|
Dzisiejszy wolumen | 656 224 |
Średni wolumen | 2.02M |
Kapitalizacja rynkowa | 0.00 |
EPS | $-0.450 ( Q2 | 2022-08-08 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-25.93 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.378 (0.73%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-10-20 | Jain Rita | Sell | 11 600 | Restricted Stock Unit |
2022-10-20 | Herron Jennifer Lyn | Sell | 17 237 | Common Stock |
2022-10-20 | Edwards Thomas A. | Sell | 15 723 | Restricted Stock Unit |
2022-10-20 | Parker Geoffrey M. | Sell | 15 723 | Restricted Stock Unit |
2022-10-20 | Kanaya Susan M | Sell | 90 968 | Restricted Stock Unit |
INSIDER POWER |
---|
-78.34 |
Last 97 transactions |
Buy: 1 451 999 | Sell: 1 420 462 |
Wolumen Korelacja
ChemoCentryx, Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
SANB | 0.835 |
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
ChemoCentryx, Inc. Korelacja - Waluta/Towar
ChemoCentryx, Inc. Finanse
Annual | 2021 |
Przychody: | $32.22M |
Zysk brutto: | $31.92M (99.06 %) |
EPS: | $-1.890 |
FY | 2021 |
Przychody: | $32.22M |
Zysk brutto: | $31.92M (99.06 %) |
EPS: | $-1.890 |
FY | 2020 |
Przychody: | $64.89M |
Zysk brutto: | $64.89M (100.00 %) |
EPS: | $-0.840 |
FY | 2019 |
Przychody: | $35.95M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.980 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
ChemoCentryx, Inc.
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej